SPY757.06−0.36%QQQ685.46−0.71%BTC/USD73,466.21−0.62%DIA524.71+0.05%GLD361.60−0.98%TLT81.07+0.19%

Gilead Sciences Inc

GILDNASDAQ

$169.73

-1.14-0.67%

Last update: Nov 12, 4:18 AM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Gilead Sciences (GILD) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Gilead Sciences (GILD) stock.

Analyst Consensus — 22 Analysts

15Buy

7Hold

# Analysts22

Latest Upgrades and Downgrades for Gilead Sciences Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	UBS	Michael Yee	PT Raise	Buy	$175→$195
—	JP Morgan	Chris Schott	PT Raise	Overweight	$170→$190
—	Citigroup	Geoff Meacham	PT Raise	Buy	$165→$188
—	Scotiabank	Louis Chen	PT Raise	Sector Outperform	$177→$200
—	TD Cowen	Tyler Van Buren	PT Raise	Buy	$160→$175
—	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$163→$183
—	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$165→$190
—	Truist Securities	Gregory Renza	PT Raise	Buy	$158→$181
—	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$126→$131
—	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$155→$175
—	Needham	Joseph Stringer	PT Raise	Buy	$170→$200
—	B of A Securities	Tim Anderson	PT Raise	Buy	$168→$172
—	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$123→$126
—	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155
—	Truist Securities	Gregory Renza	PT Raise	Buy	$150→$158
—	JP Morgan	Chris Schott	PT Raise	Overweight	$160→$170
—	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$165→$163
—	HSBC	Morten Herholdt	PT Raise	Buy	$155→$175
—	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$120→$123
—	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155

Gilead Sciences Inc

Gilead Sciences (GILD) Stock Price Target 2026

Latest Upgrades and Downgrades for Gilead Sciences Stock

Gilead Sciences (GILD) Stock Price Target 2026

Latest Upgrades and Downgrades for Gilead Sciences Stock

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PRO
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131

People Also Watch

People Also Watch

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PRO
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131

Gilead Sciences Inc

Gilead Sciences (GILD) Stock Price Target 2026

Latest Upgrades and Downgrades for Gilead Sciences Stock

Gilead Sciences (GILD) Stock Price Target 2026

Latest Upgrades and Downgrades for Gilead Sciences Stock

Analyst Ratings News

PROJP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PROTD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PROMorgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PROWells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PROTruist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRORBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131

People Also Watch

People Also Watch

Analyst Ratings News

PROJP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PROTD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PROMorgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PROWells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PROTruist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRORBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PRO
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PRO
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131